Jianxin Capital is an investment fund based in Shanghai that specializes in risk investments within the healthcare sector. The firm is supported by a professional team of nearly 20 members, each possessing extensive experience in medical and financial fields. This diverse expertise enables the team to make informed investment decisions aligned with industry trends, aimed at generating value for both enterprises and investors. The members have backgrounds in biomedical and financial sectors, both domestically and internationally, allowing them to stay informed about developments in the biopharmaceutical industry. Jianxin Capital focuses on the specific needs of the companies it invests in, providing comprehensive support in areas such as product development, industrialization, management, and financial investment. Through these efforts, Jianxin Capital aims to contribute significantly to the growth and success of its portfolio companies.
Hegeia Biotechnology is a company that focused on the research and development of siRNA, tiny nucleic acid attached delivery medicines.
Isabers
Series A in 2023
Isabers is a provider of advanced semiconductor integration technology and products, which can achieve inter-generational fusion of semiconductor materials and advanced packaging and can effectively solve the pain points of low yield, high cost, and limited performance of advanced semiconductor materials or devices, thus accelerating the development of the domestic semiconductor industry and quickly seizing the strategic high ground of international market competition.
Meike Solar
Series B in 2021
Meike Solar is engaged in the manufacturing of solar photovoltaic polycrystalline silicon wafers. The company emphasizes research and development to enhance its product offerings and utilizes integrated monitoring systems and equipment to support intelligent manufacturing processes. This approach enables Meike Solar to produce its products efficiently while minimizing costs.
Weishi Energy
Series A in 2021
Weishi Energy is a hydrogen fuel cell product research and development manufacturer, focusing on the market operation of hydrogen fuel cell technology, and is committed to promoting the low-carbon sustainable development of human energy. It is mainly engaged in the research and development, production and sales of hydrogen fuel cell products. At present, Weishi Energy has deployed five R&D centers in Shanghai, Baoding, Japan, Germany, and Canada. It has established a culturally diverse and technologically advanced R&D team, and strictly follows the V model development process to create vehicle-level fuel cell power systems and components. The company's main products include fuel cell engines, electric stacks, 35MPa/70MPa on-board hydrogen systems, bottle valves and pressure reducing valves, etc.
GeneCast Biotechnology
Series E in 2020
GeneCast Biotechnology Co., Ltd. is a Beijing-based company founded in 2014 that specializes in gene research and the development of advanced cancer diagnostic solutions. The company offers a technology platform for cell-free DNA next-generation sequencing (NGS) tests, which are used for companion diagnostics, genetic profiling, prognosis, and monitoring of various solid tumors, including lung, colorectal, liver, and breast cancers. GeneCast provides non-invasive and precise tumor diagnoses and personalized treatment guidance, leveraging high-throughput sequencing and bioinformatics. The company collaborates with hospitals and research institutions to enhance cancer treatment and genetic testing, aiming to improve patient outcomes and quality of life. GeneCast is also focused on advancing its research and clinical trials while expanding its distribution channels.
Abbisko Therapeutics
Series C in 2020
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.
Percutek Therapeutics
Series D in 2019
Percutek Therapeutics specializes in the research, development, and manufacturing of cardiovascular interventional medical devices. The company focuses on Class III minimally invasive devices aimed at diagnosing and treating a range of cardiovascular conditions. Its product portfolio includes devices for various applications, such as aortic, peripheral, and coronary interventions, as well as nerve access. By prioritizing patient safety and clinical efficacy, Percutek Therapeutics is committed to delivering high-quality solutions that enhance the treatment of vascular diseases, thereby supporting both healthcare providers and patients in achieving better health outcomes.
Leads Biolabs
Venture Round in 2019
Leads Biolabs is a biotechnology company focused on developing innovative antibody-based therapeutics to address unmet medical needs in oncology and immunological diseases. Founded in 2014 and headquartered in China, the company has established a strong research and development pipeline featuring over ten projects centered on monoclonal and bispecific antibodies for cancer immunotherapy. By concentrating on tumor immunotherapy, Leads Biolabs aims to enhance treatment outcomes and access for patients globally, thereby improving their medical conditions and overall quality of life.
Innocare
Private Equity Round in 2019
InnoCare is a biopharmaceutical company based in China, focused on discovering, developing, and commercializing innovative treatments for cancer and autoimmune diseases. The company boasts a skilled scientific team with extensive experience in drug innovation from both the U.S. and China, supported by an accomplished Scientific Advisory Board comprised of experts from prominent universities, hospitals, and the pharmaceutical sector. InnoCare's product pipeline includes several key therapies, such as orelabrutinib, ibrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune disorders. The company is also dedicated to addressing autoimmune diseases linked to abnormal B-cell or T-cell functions, positioning itself as a leader in advancing medical treatments and tackling complex health challenges.
Leads Biolabs
Series B in 2018
Leads Biolabs is a biotechnology company focused on developing innovative antibody-based therapeutics to address unmet medical needs in oncology and immunological diseases. Founded in 2014 and headquartered in China, the company has established a strong research and development pipeline featuring over ten projects centered on monoclonal and bispecific antibodies for cancer immunotherapy. By concentrating on tumor immunotherapy, Leads Biolabs aims to enhance treatment outcomes and access for patients globally, thereby improving their medical conditions and overall quality of life.
Sumgen Biotech
Series A in 2018
Sumgen is an antibody drug developer focused on creating innovative therapeutic antibody drugs for the treatment of tumors and other diseases. The company specializes in immunotherapy and immunodiagnosis, employing advanced technologies such as computer-aided design and mammalian cell display to screen and optimize antibody candidates. By leveraging its unique research and development methodologies, Sumgen aims to produce effective antibody drugs that provide patients with targeted treatment options for major diseases, including cancer.
Eastern Biotech
Angel Round in 2018
Eastern Biotech, headquartered in Beijing, specializes in the development and manufacturing of pharmaceutical products. Its primary focus is on creating treatments for diabetes and obesity through extensive medical research. Additionally, the company has developed therapeutic solutions for immune diseases and cancer, leveraging its expertise in humanized monoclonal antibodies and vaccines.
Huadao Biopharma
Angel Round in 2017
Huadao Biopharma is a biomedical company focused on cellular immunotherapy, specifically in the field of oncology. The company develops advanced CAR-T (chimeric antigen receptor-T) cell technologies, utilizing methods such as bacteria fermentation engineering and virus purification techniques. Huadao Biopharma also specializes in T cell acquisition and cell harvesting, offering healthcare practitioners valuable research resources and expertise. Its primary aim is to enhance treatment options for conditions like acute lymphoblastic leukemia and other related diseases, contributing to advancements in cancer therapies.
Leads Biolabs
Series A in 2017
Leads Biolabs is a biotechnology company focused on developing innovative antibody-based therapeutics to address unmet medical needs in oncology and immunological diseases. Founded in 2014 and headquartered in China, the company has established a strong research and development pipeline featuring over ten projects centered on monoclonal and bispecific antibodies for cancer immunotherapy. By concentrating on tumor immunotherapy, Leads Biolabs aims to enhance treatment outcomes and access for patients globally, thereby improving their medical conditions and overall quality of life.
Abbisko Therapeutics
Series A in 2017
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.
FDOG
Angel Round in 2015
FDOG is a pet-growth assistant app that provides customize pet-raising reminders.
Shejia
Angel Round in 2015
Shejia is an app for second-hand luxury goods.
LP Pharmaceuticals
Series A in 2015
LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.
Jia.com
Series B in 2015
Jia.com is a leading interior designing platform specializing in home decoration services. Established in March 2005 by Shanghai Qijia Information Technology Co., Ltd., the company offers a wide range of products including decorations, building materials, furniture, appliances, and mass consumer goods. By June 2010, Jia.com had amassed over 1.8 million registered members and conducted more than 2,000 group buying events, serving over 5 million customers. The platform has attracted nearly 12,000 businesses and 15,000 brands, processing over 1.2 million valid orders annually with a total output value exceeding 3.2 billion Yuan.
ChanGee
Private Equity Round in 2012
ChanGee is medical manufacturing company that develops medical products including surgical masks, syringes and medicines.
Hair & Yard
Series C in 2011
Hair & Yard is a hair product manufacturing company.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.